Takeda Pharmaceutical is considering revising financial results for the fiscal year ending March 2026 due to a US antitrust lawsuit. A jury verdict has recognized damages of 884,943,990 USD, pending court ruling. Reserves will be booked, and financial statements will be revised.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4502-20260519-01.pdf","jir_short_summary":"Takeda Pharmaceutical is considering revising financial results for the fiscal year ending March 2026 due to a US antitrust lawsuit. A jury verdict has recognized damages of 884,943,990 USD, pending court ruling. Reserves will be booked, and financial statements will be revised.","jir_summary":"### Overview of Financial Results and Lawsuit\nTakeda Pharmaceutical's jury verdict in the US antitrust lawsuit has recognized damages of 884,943,990 USD, with the court's ruling pending. The damages are subject to triple damages, and reserves are planned to be booked with an adjustment to the financial results for the fiscal year ending March 2026. The lawsuit relates to a 2014 settlement agreement involving generic drug launches and patent infringement claims. The company intends to contest the lawsuit through legal channels.\n\n### Future Actions and Outlook\nThe company is currently reviewing the reserve amount, which will be reflected in the financial statements after determination. The timing and amount of the court ruling could impact the financial position, but it is expected to have minimal effect on the FY2025 results. The company will continue to handle legal matters and disclose information as appropriate.","jir_financial_highlights":"Damages Awarded: 884,943,990 USD (Recognized by jury verdict)\nThreefold damages applicable amount according to court ruling: 474,897,965 USD (wholesaler class) + 346,837,646 USD (retail pharmacy class) (Automatically tripled by court judgment)\nFinancial adjustment for the fiscal year ending March 2026: Undecided (To be revised after reserve amount is finalized)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #IRType:financial_summary, #JapaneseStocks","jir_key_figures":"Damages awarded: 884,943,990 USD (recognized by jury verdict)\nThreefold damages: 474,897,965 USD (wholesaler class) + 346,837,646 USD (retail pharmacy class)\nFinancial adjustment planning: to be revised after reserve is finalized for FY2026","jir_meta_title":"\u3010Takeda Pharmaceutical\u3011 US Lawsuit and Financial Adjustment \uff5c May 2026","jir_meta_description":"Takeda Pharmaceutical is considering damage award recognition and financial statement revisions due to a US antitrust lawsuit. Details on reserve bookings and upcoming financial statement adjustments are provided.","jir_og_title":"\u3010Takeda Pharmaceutical\u3011 US Lawsuit and Financial Adjustment \uff5c May 2026","jir_og_description":"Takeda Pharmaceutical plans to revise financial statements following the jury verdict in the US lawsuit. Details on damages and future actions are explained.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-52738","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n